Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 9, 2014 - Issue 1
Submit an article Journal homepage
83
Views
1
CrossRef citations to date
0
Altmetric
Reviews

The value of genetic screening in medullary thyroid cancer

Theodora PappaDepartment of Medical Therapeutics, Endocrine Unit, Athens University School of Medicine, Alexandra Hospital, Athens, GreeceCorrespondence[email protected]
&
Maria AlevizakiDepartment of Medical Therapeutics, Endocrine Unit, Athens University School of Medicine, Alexandra Hospital, Athens, Greece;Department of Endocrinology, Metabolism and Diabetes, Athens University School of Medicine, Evgenideion Hospital, Athens, Greece
Pages 19-29 | Published online: 13 Dec 2013

References

  • Romei C, Pardi E, Cetani F, Elisei R. Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J. Oncol. 2012, 705036 (2012).
  • Machens A, Lorenz K, Sekulla C et al. Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. Eur. J. Endocrinol. 168(3), 307–314 (2013).
  • Spinelli C, Di Giacomo M, Costanzo S, Elisei R, Miccoli P. Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes. J. Pediatr. Surg. 45(8), 1610–1616 (2010).
  • Elisei R, Cosci B, Romei C et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 93(3), 682–687 (2008).
  • Mian C, Pennelli G, Barollo S et al. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur. J. Endocrinol. 164(6), 971–976 (2011).
  • Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42(2), 581–588 (1985).
  • Ishizaka Y, Itoh F, Tahira T et al. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 4(12), 1519–1521 (1989).
  • Santoro M, Carlomagno F, Romano A et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267(5196), 381–383 (1995).
  • Machens A, Lorenz K, Dralle H. Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities. J. Intern. Med. 266(1), 114–125 (2009).
  • Simpson NE, Kidd KK, Goodfellow PJ et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328(6130), 528–530 (1987).
  • Mathew CG, Chin KS, Easton DF et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328(6130), 527–528 (1987).
  • Mulligan LM, Kwok JB, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363(6428), 458–460 (1993).
  • Carlson KM, Dou S, Chi D et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl Acad. Sci. USA 91(4), 1579–1583 (1994).
  • Eng C, Smith DP, Mulligan LM et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum. Mol. Genet. 3(2), 237–241 (1994).
  • Hofstra RM, Landsvater RM, Ceccherini I et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367(6461), 375–376 (1994).
  • Mulligan LM, Eng C, Healey CS et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat. Genet. 6(1), 70–74 (1994).
  • Xue F, Yu H, Maurer LH et al. Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests. Hum. Mol. Genet. 3(4), 635–638 (1994).
  • Lips CJ, Landsvater RM, Höppener JW et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N. Engl. J. Med. 331(13), 828–835 (1994).
  • Schuffenecker I, Billaud M, Calender A et al. RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum. Mol. Genet. 3(11), 1939–1943 (1994).
  • Mulligan LM, Marsh DJ, Robinson BG et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J. Intern. Med. 238(4), 343–346 (1995).
  • Eng C, Clayton D, Schuffenecker I et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276(19), 1575–1579 (1996).
  • Benej M, Bendlova B, Vaclavikova E, Poturnajova M. Establishing high resolution melting analysis: method validation and evaluation for c-RET proto-oncogene mutation screening. Clin. Chem. Lab. Med. 50(1), 51–60 (2011).
  • Elisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V, Williams GR. 2012 European Thyroid Association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur. Thyroid J. 1, 216–231 (2012).
  • Elisei R, Cosci B, Romei C et al. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J. Clin. Endocrinol. Metab. 89(11), 5823–5827 (2004).
  • Erlic Z, Hoffmann MM, Sullivan M et al. Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. J. Clin. Endocrinol. Metab. 95(1), 308–313 (2010).
  • Cosci B, Vivaldi A, Romei C et al. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr. Relat. Cancer 18(5), 603–612 (2011).
  • Fernández RM, Navarro E, Antiñolo G, Ruiz-Ferrer M, Borrego S. Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients. Int. J. Mol. Med. 17(4), 575–581 (2006).
  • Muzza M, Cordella D, Bombled J et al. Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro. Eur. J. Endocrinol. 162(4), 771–777 (2010).
  • Borrello MG, Aiello A, Peissel B et al. Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism. Endocr. Relat. Cancer 18(4), 519–527 (2011).
  • Machens A, Frank-Raue K, Lorenz K, Rondot S, Raue F, Dralle H. Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer. Clin. Endocrinol. (Oxf.) 76(5), 691–697 (2012).
  • Machens A, Spitschak A, Lorenz K, Pützer BM, Dralle H. Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation? Clin. Endocrinol. (Oxf.) 75(6), 801–805 (2011).
  • Castellone MD, Verrienti A, Magendra Rao D et al. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization. Clin. Endocrinol. (Oxf.) 73(4), 529–534 (2010).
  • Bergant D, Hocevar M, Besic N, Glavac D, Korosec B, Caserman S. Hereditary medullary thyroid cancer in Slovenia--genotype-phenotype correlations. Wien. Klin. Wochenschr. 118(13–14), 411–416 (2006).
  • Patocs A, Klein I, Szilvasi A et al. Genotype-phenotype correlations in Hungarian patients with hereditary medullary thyroid cancer. Wien. Klin. Wochenschr. 118(13–14), 417–421 (2006).
  • Pinna G, Orgiana G, Riola A et al. RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype. Thyroid 17(2), 101–104 (2007).
  • Abdelhakim A, Barlier A, Kebbou M et al. RET genetic screening in patients with medullary thyroid cancer: the Moroccan experience. J. Cancer Res. Ther. 5(3), 198–202 (2009).
  • Neocleous V, Skordis N, Portides G et al. RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2. J. Endocrinol. Invest. 34(10), 764–769 (2011).
  • Romei C, Cosci B, Renzini G et al. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin. Endocrinol. (Oxf.) 74(2), 241–247 (2011).
  • Romei C, Mariotti S, Fugazzola L et al. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur. J. Endocrinol. 163(2), 301–308 (2010).
  • Frank-Raue K, Höppner W, Frilling A et al. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. J. Clin. Endocrinol. Metab. 81(5), 1780–1783 (1996).
  • Machens A, Gimm O, Hinze R, Höppner W, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J. Clin. Endocrinol. Metab. 86(3), 1104–1109 (2001).
  • Jindrichová S, Vcelák J, Vlcek P, Neradilová M, Nemec J, Bendlová B. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. J. Endocrinol. 183(2), 257–265 (2004).
  • Elisei R, Romei C, Cosci B et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J. Clin. Endocrinol. Metab. 92(12), 4725–4729 (2007).
  • Paszko Z, Sromek M, Czetwertynska M et al. The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred’s from Central Poland. Cancer Invest. 25(8), 742–749 (2007).
  • Machens A, Dralle H. Familial prevalence and age of RET germline mutations: implications for screening. Clin. Endocrinol. (Oxf.) 69(1), 81–87 (2008).
  • Raue F, Frank-Raue K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens) 8(1), 23–28 (2009).
  • Gimm O, Marsh DJ, Andrew SD et al. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J. Clin. Endocrinol. Metab. 82(11), 3902–3904 (1997).
  • Niccoli-Sire P, Murat A, Rohmer V et al. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. J. Clin. Endocrinol. Metab. 86(8), 3746–3753 (2001).
  • Figlioli G, Landi S, Romei C, Elisei R, Gemignani F. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat. Res. 752(1), 36–44 (2013).
  • Bethanis S, Koutsodontis G, Palouka T et al. A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones (Athens) 6(2), 152–156 (2007).
  • Sarika HL, Papathoma A, Garofalaki M et al. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece. Clin. Endocrinol. (Oxf.) 77(6), 857–862 (2012).
  • Peppa M, Boutati E, Kamakari S et al. Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene. Eur. J. Endocrinol. 159(6), 767–771 (2008).
  • Oliveira MN, Hemerly JP, Bastos AU et al. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo. Thyroid 21(9), 975–985 (2011).
  • Castro MR, Thomas BC, Richards ML, Zhang J, Morris JC. Multiple endocrine neoplasia type 2A due to an exon 8 (G533C) mutation in a large North American kindred. Thyroid doi:10.1089/thy.2012.0599 (2013) ( Epub ahead of print).
  • Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J. Clin. Endocrinol. Metab. 98(8), 3149–3164 (2013).
  • Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86(12), 5658–5671 (2001).
  • Menko FH, van der Luijt RB, de Valk IA et al. Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J. Clin. Endocrinol. Metab. 87(1), 393–397 (2002).
  • Conzo G, Circelli L, Pasquali D et al. Lessons to be learned from the clinical management of a MEN 2A patient bearing a novel 634/640/700 mutation of the RET proto-oncogene. Clin. Endocrinol. (Oxf.) 77(6), 934–946 (2012).
  • Tessitore A, Sinisi AA, Pasquali D et al. A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene. J. Clin. Endocrinol. Metab. 84(10), 3522–3527 (1999).
  • Dvorakova S, Vaclavikova E, Ryska A et al. Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds. Exp. Clin. Endocrinol. Diabetes 114(4), 192–196 (2006).
  • Bartsch DK, Hasse C, Schug C, Barth P, Rothmund M, Höppner W. A RET double mutation in the germline of a kindred with FMTC. Exp. Clin. Endocrinol. Diabetes 108(2), 128–132 (2000).
  • Kloos RT, Eng C, Evans DB, et al.; American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19(6), 565–612 (2009).
  • Valente FO, Dias da Silva MR, Camacho CP et al. Comprehensive analysis of RET gene should be performed in patients with MEN 2 syndrome and no apparent genotype-phenotype correlation: an appraisal of p.Y791F and p.C634Y RET mutations in five unrelated Brazilian families. J. Endocrinol. Invest. doi:10.3275/8997 (2013) ( Epub ahead of print).
  • Wiench M, Wygoda Z, Gubala E et al. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J. Clin. Oncol. 19(5), 1374–1380 (2001).
  • Blom CB, Ceolin L, Romitti M, Siqueira D, Maia AL. The rare intracellular RET mutation p.Ser891Ala in an apparently sporadic medullary thyroid carcinoma: a case report and review of the literature. Arq. Bras. Endocrinol. Metabol. 56(8), 586–591 (2012).
  • Guerrero IM, Pessoa CH, Olmedo DB et al. Analysis of inherited genetic variants in ret proto-oncogene of Brazilian patients with apparently sporadic medullary thyroid carcinoma. Thyroid 16(1), 9–15 (2006).
  • Elisei R, Cosci B, Romei C et al. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J. Clin. Endocrinol. Metab. 89(7), 3579–3584 (2004).
  • Lindsey SC, Kunii IS, Germano-Neto F et al. Extended RET gene analysis in patients with apparently sporadic medullary thyroid cancer: clinical benefits and cost. Horm. Cancer 3(4), 181–186 (2012).
  • Seri M, Celli I, Betsos N, Claudiani F, Camera G, Romeo G. A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. Clin. Genet. 51(2), 86–90 (1997).
  • Verga U, Fugazzola L, Cambiaghi S et al. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin. Endocrinol. (Oxf.) 59(2), 156–161 (2003).
  • Rothberg AE, Raymond VM, Gruber SB, Sisson J. Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. Thyroid 19(6), 651–655 (2009).
  • Fialkowski EA, DeBenedetti MK, Moley JF, Bachrach B. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. J. Pediatr. Surg. 43(1), 188–190 (2008).
  • Vaclavikova E, Kavalcova L, Skaba R et al. Hirschsprung’s disease and medullary thyroid carcinoma: 15-year experience with molecular genetic screening of the RET proto-oncogene. Pediatr. Surg. Int. 28(2), 123–128 (2012).
  • Moore SW, Zaahl M. Familial associations in medullary thyroid carcinoma with Hirschsprung disease: the role of the RET-C620 “Janus” genetic variation. J. Pediatr. Surg. 45(2), 393–396 (2010).
  • Wells SA Jr, Skinner MA. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp. Clin. Endocrinol. Diabetes 106(1), 29–34 (1998).
  • Machens A, Niccoli-Sire P, Hoegel J et al. Early malignant progression of hereditary medullary thyroid cancer. N. Engl. J. Med. 349(16), 1517–1525 (2003).
  • Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N. Engl. J. Med. 353(11), 1105–1113 (2005).
  • Schreinemakers JM, Vriens MR, Valk GD et al. Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study. World J. Surg. 34(4), 852–860 (2010).
  • Rohmer V, Vidal-Trecan G, Bourdelot A et al. Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d’Etude des Tumeurs Endocrines. J. Clin. Endocrinol. Metab. 96(3), E509–E518 (2011).
  • Kouvaraki MA, Shapiro SE, Perrier ND et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroidcancer and associated endocrine tumors. Thyroid 15(6), 531–544 (2005).
  • Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H. Advances in the management of hereditary medullary thyroid cancer. J. Intern. Med. 257(1), 50–59 (2005).
  • Elisei R, Romei C, Renzini G et al. The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J. Clin. Endocrinol. Metab. 97(2), 426–435 (2012).
  • Frank-Raue K, Rybicki LA, Erlic Z et al. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum. Mutat. 32(1), 51–58 (2011).
  • Shepet K, Alhefdhi A, Lai N, Mazeh H, Sippel R, Chen H. Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival. Ann. Surg. Oncol. 20(5), 1451–1455 (2013).
  • Machens A, Lorenz K, Dralle H. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann. Surg. 250(2), 305–310 (2009).
  • Jarzab B, Szpak-Ulczok S, Wloch J, Czarniecka A, Krajewska J. Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers - the role of Ct serum level. Thyroid Res. 6(Suppl. 1), S9 (2013).
  • Qi XP, Zhao JQ, Du ZF et al. Prophylactic thyroidectomy for MEN 2-related medullary thyroid carcinoma based on predictive testing for RET proto-oncogene mutation and basal serum calcitonin in China. Eur. J. Surg. Oncol. 39(9), 1007–1012 (2013).
  • Raue F, Rondot S, Schulze E, Szpak-Ulczok S, Jarzab B, Frank-Raue K. Clinical utility gene card for: multiple endocrine neoplasia type 2. Eur. J. Hum. Genet. 20(1) (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.